William J. Sandborn
0000-0002-3314-7960
Publication & Citation Trends
Publications
2,107 total
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
Cited by 5
Semantic Scholar
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
Cited by 7
Semantic Scholar
TWO-YEAR RESULTS OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION THERAPY - FROM LIBERTY-CD AND LIBERTY-UC
Cited by 1
Semantic Scholar
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn’s Disease OA
Cited by 2
Semantic Scholar
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis OA
Cited by 34
Semantic Scholar
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial OA
Cited by 29
Semantic Scholar
Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE COLITIS: 2-YEAR EXTENSION RESULTS OF THE LIBERTY-UC STUDY
Cited by 0
Semantic Scholar
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn’s disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies OA
Cited by 2
Semantic Scholar
Research Topics
Inflammatory Bowel Disease
(1666)
Microscopic Colitis
(1150)
Eosinophilic Esophagitis
(283)
Immunodeficiency and Autoimmune Disorders
(187)
Helicobacter pylori-related gastroenterology studies
(175)
Affiliations
Semmelweis University
Andrews University
St. Andrews University
University of North Carolina at Chapel Hill
Ulsan College